SummaryWegovy’s newly launched pill form, approved for obesity and cardiovascular risk reduction, is rolling out across US pharmacies. Studies show up to 13.6 percent average weight loss, rising to 16.6 percent with diet changes. Experts say the cheaper pill could expand access, though digestive side effects remain common in patients overall.